Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)

4.61
Delayed Data
As of 4:01pm ET
 +0.06 / +1.32%
Today’s Change
3.47
Today|||52-Week Range
8.79
-2.95%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$224.4M

Company Description

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Contact Information

Aeglea Biotherapeutics, Inc.
805 Las Cimas Parkway
Austin Texas 78746
P:(512) 942-2935
Investor Relations:
(512) 900-3661

Employees

Shareholders

Other institutional46.72%
Individual stakeholders22.91%
Mutual fund holders22.30%

Top Executives

Anthony G. QuinnPresident, Chief Executive Officer & Director
Leslie SloanChief Operating Officer
Jonathan D. AlspaughChief Financial Officer
Steven WeberChief Accounting Officer, VP & Controller
Scott W. RowlinsonVice President-Research